dapagliflozin
astrazeneca
['dapagliflozin', 'ade ', 'cardio']
results from deliver made dapagliflozin the third sglt2 inhibitor to benefit patients with hfpef, cementing a new, ejection fraction-agnostic management approach. #esccongress #cardiotwitter
theheartorg | Medscape Cardiology is your best source for cardiovascular disease news online. https://t.co/Q8t8IR82zV